Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients

Detalhes bibliográficos
Autor(a) principal: Campanilho-Marques, Raquel
Data de Publicação: 2020
Outros Autores: Deakin, Claire T., Simou, Stefania, Papadopoulou, Charalampia, Wedderburn, Lucy R., Pilkington, Clarissa A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/46680
Resumo: © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.
id RCAP_034c76c79e90156fc2294160e60ce9c2
oai_identifier_str oai:repositorio.ul.pt:10451/46680
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patientsInfliximabAdalimumabJuvenile dermatomyositisBiologic therapyP rheumatology© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.Background: Anti-TNF treatment may be useful for the treatment of patients with refractory juvenile dermatomyositis (JDM). The aim of this study was to describe the use of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment. Methods: Sixty children recruited to the UK JDM Cohort and Biomarker Study that had received at least 3 months of anti-TNF treatment (infliximab or adalimumab) were studied. Childhood Myositis Assessment Scale (CMAS). Manual Muscle Testing (MMT8) and physician’s global assessment (PGA) were recorded. Skin disease was assessed using the modified skin disease activity score (DAS). Data were analysed using Friedman’s test for repeated measures analysis of variance. Results: Compared to baseline, there were improvements at 6 and 12 months in skin disease (χ 2 (2) = 15.52, p = 0.00043), global disease (χ 2 (2) = 8.14, p = 0.017) and muscle disease (CMAS χ 2 (2) = 17.02, p = 0.0002 and MMT χ 2 (2) = 10.56, p = 0.005) in infliximab patients. For patients who switched from infliximab to adalimumab, there was improvement in global disease activity (χ 2 (2) = 6.73, p = 0.03), and trends towards improvement in CMAS, MMT8 and modified DAS. The median initial prednisolone dose was 6 [0–10] mg, and final was 2.5 [0–7.5] mg (p < 0.0001). Fifty-four per cent of patients had a reduction in the number and/or size of calcinosis lesions. Twenty-five per cent switched their anti-TNF treatment from infliximab to adalimumab. 66.7%of the switches were to improve disease control, 26.7% due to adverse events and 6.6% due to patient preference. A total of 13.9 adverse reactions occurred in 100 patient-years, of which 5.7 were considered serious. Conclusion: Reductions in muscle and skin disease, including calcinosis, were seen following treatment with infliximab and adalimumab.Springer NatureRepositório da Universidade de LisboaCampanilho-Marques, RaquelDeakin, Claire T.Simou, StefaniaPapadopoulou, CharalampiaWedderburn, Lucy R.Pilkington, Clarissa A.2021-03-05T12:33:38Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/46680engArthritis Res Ther. 2020 Apr 15;22(1):791478-635410.1186/s13075-020-02164-51478-6362info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:49:06Zoai:repositorio.ul.pt:10451/46680Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:58:47.912395Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
title Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
spellingShingle Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Campanilho-Marques, Raquel
Infliximab
Adalimumab
Juvenile dermatomyositis
Biologic therapy
P rheumatology
title_short Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
title_full Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
title_fullStr Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
title_full_unstemmed Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
title_sort Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
author Campanilho-Marques, Raquel
author_facet Campanilho-Marques, Raquel
Deakin, Claire T.
Simou, Stefania
Papadopoulou, Charalampia
Wedderburn, Lucy R.
Pilkington, Clarissa A.
author_role author
author2 Deakin, Claire T.
Simou, Stefania
Papadopoulou, Charalampia
Wedderburn, Lucy R.
Pilkington, Clarissa A.
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Campanilho-Marques, Raquel
Deakin, Claire T.
Simou, Stefania
Papadopoulou, Charalampia
Wedderburn, Lucy R.
Pilkington, Clarissa A.
dc.subject.por.fl_str_mv Infliximab
Adalimumab
Juvenile dermatomyositis
Biologic therapy
P rheumatology
topic Infliximab
Adalimumab
Juvenile dermatomyositis
Biologic therapy
P rheumatology
description © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2021-03-05T12:33:38Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/46680
url http://hdl.handle.net/10451/46680
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Arthritis Res Ther. 2020 Apr 15;22(1):79
1478-6354
10.1186/s13075-020-02164-5
1478-6362
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134534173720576

Registros relacionados